Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitch Raponi

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and PlasmaKaren L Reckamp, Vladislava O Melnikova, Chris Karlovich, et al.
Molecular Cancer Therapeutics|April 12, 2014
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparingRobert Tjin Tham Sjin, Kwangho Lee, Annette O Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and PlasmaKaren L Reckamp, Vladislava O Melnikova, Chris Karlovich, et al.
Molecular Cancer Therapeutics|April 12, 2014
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparingRobert Tjin Tham Sjin, Kwangho Lee, Annette O Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Pageof 4